An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Previously Treated in Protocol MDX060-03
- Conditions
- Relapsed or Refractory Hodgkin’s DiseaseMedDRA version: 5.0Level: LLTClassification code 10020266
- Registration Number
- EUCTR2004-005040-27-GB
- Lead Sponsor
- Medarex, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie MDX-060's anti-CD154 monoclonal antibody activity in relapsed/refractory Hodgkin’s disease?
How does MDX-060 compare to brentuximab vedotin or PD-1 inhibitors in treating relapsed/refractory Hodgkin’s disease?
Which biomarkers correlate with response to anti-CD154 therapy in EUCTR2004-005040-27-GB Hodgkin’s disease patients?
What are the immune-related adverse events associated with MDX-060 in Hodgkin’s disease extension trials?
Are there combination strategies involving MDX-060 and checkpoint inhibitors for CD154-expressing Hodgkin’s lymphoma?